195 related articles for article (PubMed ID: 15582280)
1. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis.
Dedeoglu A; Cormier K; Payton S; Tseitlin KA; Kremsky JN; Lai L; Li X; Moir RD; Tanzi RE; Bush AI; Kowall NW; Rogers JT; Huang X
Exp Gerontol; 2004; 39(11-12):1641-9. PubMed ID: 15582280
[TBL] [Abstract][Full Text] [Related]
2. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
3. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice.
Lee JY; Friedman JE; Angel I; Kozak A; Koh JY
Neurobiol Aging; 2004; 25(10):1315-21. PubMed ID: 15465629
[TBL] [Abstract][Full Text] [Related]
4. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim MB; Weinreb O; Mandel S
J Neurochem; 2006 Apr; 97(2):527-36. PubMed ID: 16539659
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
6. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
[TBL] [Abstract][Full Text] [Related]
8. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI
Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis.
Carro E; Trejo JL; Gerber A; Loetscher H; Torrado J; Metzger F; Torres-Aleman I
Neurobiol Aging; 2006 Sep; 27(9):1250-7. PubMed ID: 16183170
[TBL] [Abstract][Full Text] [Related]
10. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
Mandel S; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
[TBL] [Abstract][Full Text] [Related]
11. Metal exposure and Alzheimer's pathogenesis.
Liu G; Huang W; Moir RD; Vanderburg CR; Lai B; Peng Z; Tanzi RE; Rogers JT; Huang X
J Struct Biol; 2006 Jul; 155(1):45-51. PubMed ID: 16503166
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels.
Pacheco-Quinto J; Rodriguez de Turco EB; DeRosa S; Howard A; Cruz-Sanchez F; Sambamurti K; Refolo L; Petanceska S; Pappolla MA
Neurobiol Dis; 2006 Jun; 22(3):651-6. PubMed ID: 16516482
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP.
Li L; Zhang X; Yang D; Luo G; Chen S; Le W
Neurobiol Aging; 2009 Jul; 30(7):1091-8. PubMed ID: 18063223
[TBL] [Abstract][Full Text] [Related]
15. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
[TBL] [Abstract][Full Text] [Related]
16. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology.
Maynard CJ; Cappai R; Volitakis I; Cherny RA; Masters CL; Li QX; Bush AI
J Inorg Biochem; 2006 May; 100(5-6):952-62. PubMed ID: 16574231
[TBL] [Abstract][Full Text] [Related]
17. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.
Lafay-Chebassier C; Paccalin M; Page G; Barc-Pain S; Perault-Pochat MC; Gil R; Pradier L; Hugon J
J Neurochem; 2005 Jul; 94(1):215-25. PubMed ID: 15953364
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
19. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host.
Meyer-Luehmann M; Coomaraswamy J; Bolmont T; Kaeser S; Schaefer C; Kilger E; Neuenschwander A; Abramowski D; Frey P; Jaton AL; Vigouret JM; Paganetti P; Walsh DM; Mathews PM; Ghiso J; Staufenbiel M; Walker LC; Jucker M
Science; 2006 Sep; 313(5794):1781-4. PubMed ID: 16990547
[TBL] [Abstract][Full Text] [Related]
20. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
Opazo C; Luza S; Villemagne VL; Volitakis I; Rowe C; Barnham KJ; Strozyk D; Masters CL; Cherny RA; Bush AI
Aging Cell; 2006 Feb; 5(1):69-79. PubMed ID: 16441845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
